The relationship of various factors in the pathogenesis of atherosclerosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 2, 1998, Pages 105-110

  Sönmez, Hüseyin ^a   Süer, Selma ^a   Ulutin, Turgut ^a   Kökoǧlu, Emine ^a   Üçişik, Nergiz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary heart disease; Fibronectin; Lipid parameters; Sialidase; tPA PAI 1 complex

Indexed keywords

CHOLESTEROL; FIBRONECTIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; SIALIDASE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; FIBRINOLYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; PATHOGENESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2642678417     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400205     Document Type: Article

References (65)

1. Davies MJ, Woolf N. Atherosclerosis: what is it and why does it occur? Br Heart. J 1993;69:3.
2. Schwanz CJ, Valente AJ, Sprugue EA. A modern view of atherogenesis. Am J Cardiol 1993;71:9.
3. Chobanian AV. Pathophysiology of atherosclerosis. Am J Cardiol 1992;70:3.
4. Morel DW, DiCorelto PE, Chisolm G. Endothelial and smooth muscle cells alter LDL in vitro by free radical oxidation. Arteriosclerosis 1984;4:357.
5. Steinbrecher UP, Eisher M, Sitztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 1984;25:1109.
6. Gonen B, Fallon JJ, Baker SA. Immunogenicity of malondialdehyde modified low density lipoproteins: studies with monoclonal antibodies. Arteriosclerosis 1987;65:265.
7. Mol MJTM, Demacker PNM, Stalenhoef AFH. The role of modification of lipoproteins and of the immune system in early atherogenesis. NJ Med 1993;43:83.
8. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation in human aortic intimal cells-the role of lipoprotein aggregation. Ear J Clin Chem Clin Biochem 1992;30:171.
9. Chisolm GM, Irwin KC, Penn MS. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 1992;41:61.
10. Noguchi N, Gotoh N, Niki E. Dynamics of the oxidation of low density lipoprotein induced by free radicals. Biochem Biophys Acta 1993; 1168:348.
11. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992;41:67.
12. Curtiss LK, Witztum JL. Plasma lipoproteins A-I, A-II, B, C-I and E are glycosylated in hyperglycemic diabetic subjects. Diabetes 1985;34:452.
13. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995.
14. Steinberg D, Parthasarathy S, Carew T, et al. Beyond cholesterol. Modifications of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:915.
15. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes. Diabetes Med 1991;8:411.
16. Orckhov AN, Tertov VV, Mukhin DN, Mikhailenko IA. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells. Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun 1989;162:206.
17. Orekhov AN, Tertov VV, Mukhin DN, Kabakov AE. Modified (desialylated) low density lipoprotein and autoantibodies against -lipoprotein circulating in the blood of atheroselerotic patients cause atherosclerotic manifestation in aortic cell culture. In: Descovich GC, ed. Atherosclerosis and Cardiovascular Disease. Bologna: Editrice Composition, Vol. 4, 1989:523.
18. Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 1981;38:51.
19. Rhoads GG, Dahlen G, Berg K. et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986;256:2540.
20. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a) fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:241.
21. Salonen E-M, Jauhiainen M, Zardi L, et al. Lp(a) lipoprotein has serine proteinase activity that can cleave fibronectin. EMBO J 1989;8:4035.
22. Balkuv-Ulutin Ş. Fibrinolytic system in atherosclerosis. Semin Thromb Haemost 1986; 12:91.
23. Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Haemost 1988;14:180.
24. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165.
25. Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989;339: 301.
26. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator hinds to and is inhibited by surface-bound lipoprotein (a) and low-density lipoprotein. Biochem 1991;30:6671.
27. Edelberg JM, Gonzales-Gronow M, Pizzo SV. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochem 1989;28:2370.
28. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
29. Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994;71: 504.
30. Hamsten A, Wiman B, Defaire U, Blumbaeck M. Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Meet 1985;313:1557.
31. Alon R, Bayer EA, Wilchek M. A coupled enzyme assay for measurement of sialidase activity. J Biochem Biophys Methods 1991;22:23.
32. Nobel RP. Electrophoretic separation of plasma lipoprotein in agarose gel. J Lipid Res 1968;9:693.
33. Ross R, Glomset J. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:420.
34. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579.
35. Hodenberg E, Kreuzer J, Hautmann M, et al. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1991;67:1349.
36. Eaton DL, Fless GM, Kohr WJ. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84:3224.
37. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847.
38. Walton KW, Hitchens J, Magnami HN, Khan M. A study of methods of identification and estimation of Lp(a) lipoproteins and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis 1974;20:323.
39. Loscalzo J. Lipoprotein (a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672.
40. Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991;56:2459.
41. Hansen JB, Huseby NE, Sandset PM, et al. Tissue-factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994;14: 223.
42. Ulutin ON. Haemostasis and atherosclerosis. In: Neri Seneri GG, ed. Thrombosis An Update, Florence: Scientific Press, 1992;61.
43. Ulutin ON. Haemostasis and Atherosclerosis. In: Poller L, ed. Recent Advances In Blood Coagulation, Edinburg: Churchill Livingstone Press, 1991;53.
44. Kostner GM, Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans. Eur Heart J 1990;11: 184.
45. Stenman S, Von Smitten K, Vaheri A. Fibronectin and atherosclerosis. Acta Med Scand 1980;642(suppl): 165.
46. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine. I Morphology of the intima in Pre-lesion stages. Am J Pathol 1979;95:775.
47. Brown DL, Philips FR, Damsky CH, et al. Synthesis and expression of the fibroblast fibronectin receptor in human monocytes. J Clin Invest 1989;84:366.
48. Ehnholm C, Jauhiainen M, Metso J. Interaction of lipoprotein (a) with fibronectin and its potential role in atherogenesis. Eur Heart J 1990;11:190.
49. Rovin BH, Tan LC. LDL stimulates mesengial fibronectin production and chemoattactant expression. Kidney Int 1993;43:218.
50. Tamkon JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 1983;258:4641.
51. Jung S, Jung G, Tranzer A, Dörr R. Modifications sanguines de la fibronectine plasmatique au cours de divers neoplasemes. Press Méd 1986;15:197.
52. Eijan AM, Puricelli L, Bal de Kier-Joffe E, et al. Serial analysis of fibronectin concentration in plasma of patients with benign and malignant breast diseases. Cancer 1986;57:1345.
53. Bindwell CR, Gospudarowicz D, Nicolson GI. Identification, localization and role of fibronectin in cultured bovine endothelial cells. Proc Natl Acad Sci USA 1978;75:3273.
54. Macarak EJ, Kirby E, Kirk TK, Kefalides NA, Synthesis of cold insoluble globulin by cultured calf endothelial cells. Proc Natl Acad Sci USA 1978;75:262.
55. Jaffe EA, Mosher DF. Synthesis of fibronectin by cultured human endothelial cells. J Exp Med 1978;151:602.
56. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785.
57. Tertov VV, Orekhov AN, Martsenyuk ON, et al. Low density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989;50:337.
58. Mukhin DN, Tertov VV, Kacharava AG, Orekhov AN. Desialylated low density lipoproteins atherogenic lipoproteins occurring in blood of patients with coronary atherosclerosis. Biull Eksp Biol Med 1990;110:138.
59. Tertov VV, Sobenin IA, Gevara KH, et al. Carbohydrate composition of native and desialylated low density lipoproteins in the plasma of patients with coronary atherosclerosis. Kardiologia 1992;32:57.
60. Tertov VV, Sobenin IA, Tonevitsky AG, et al. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun 1990; 167:1122.
61. Tertov VV, Sobenin IA, Orekhov AN. Characterization of desialylated low density lipoproteins which cause intracellular lipid accumulation. Int J Tiss Reac 1992;14:155.
62. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Multiple modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992;67:665.
63. Orekhov AN, Tertov VV, Mukhin DN. Desialyated low density lipoprotein-naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis 1991;86:153.
64. Yashiro A, O'Neil J, Hoff HF. Insoluble complex formation of lipoprotein (a) with low density lipoprotein in the presence of calcium ions. J Biol Chem 1993;268:4709.
65. Fless GM, Zummalen ME, Scanu AM. Physicochemical properties of apolipoprotein (a) and lipoprotein (a) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem 1986;261: 8712.